Simple Insulin Dose Adjustment Using 3-3-1 Algorithm in Japanese Patients with Type 2 Diabetes: Start Kanazawa Study (Self-Titration Aggressive Algorithm with Glargine Trial)
- 1 Department of Internal Medicine, Japan Community Health care Organization (JCHO) Kanazawa Hospital, Kanazawa, Japan
- 2 Department of Internal Medicine, Japan Community Health care Organization (JCHO) Kanazawa Hospital, Kanazawa, Japan
- 3 Department of Internal Medicine, Japan Community Health care Organization (JCHO) Kanazawa Hospital, Kanazawa, Japan
- 4 Department of Internal Medicine, Japan Community Health care Organization (JCHO) Kanazawa Hospital, Kanazawa, Japan
- 5 Department of Internal Medicine, Japan Community Health care Organization (JCHO) Kanazawa Hospital, Kanazawa, Japan
Abstract
W e implemented a 3-3-1 algorithm in order to provide safe and simple self-titration in patients who newly initiated BOT as well as who were already on BOT and evaluated its utility in clinical setting. A total of 46 patients, 21 patients in the newly-initiated group and 25 patients in the existing BOT group performed dose adjustment using 3-3-1 algorithm. HbA1c was significantly improved 4 weeks after the initiation from 8.5% ± 1.2% at baseline to 7.3% ± 0.7% at the final evaluation (p < 0.01, vs. Baseline). The average daily insulin units increased throughout the study period from 10.1 ± 6.7 at baseline to 14.6 ± 8.9 units at the final evaluation. Weight didn’t significantly change throughout the study (p = 0.12). The incidents of hypoglycemia were 0.8/month during the insulin dose self-adjustment period and 0.4/month during the follow-up period. The 3-3-1 algorithm using insulin glargine provided a safe and simple dose adjustment and demonstrated its utility in patients who were newly introduced to insulin treatment as well as who were already on BOT.
- Inzucchi, S.E., et al. (2012) Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35, 1364-1379. http://dx.doi.org/10.2337/dc12-0413
- Ishii, H., et al. (2008) Improvement of Glycemic Control and Quality-of-Life by Insulin Lispro Therapy: Assessing Benefits by ITR-QOL Questionnaires. Diabetes Research and Clinical Practice, 81, 169-178. http://dx.doi.org/10.1016/j.diabres.2008.03.020
- Inzucchi, S.E., et al. (2015) A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38, 140-149. http://dx.doi.org/10.2337/dc14-2441
- Furukawa, K., et al. (2014) Glargine Dose Optimization using ALOHA Dose Calculator with T2DM in Japan (GOLD-J Study). Journal of New Remedies & Clinics, 63, 771-777.
- Davies, M., et al. (2005) Improvement of Glycemic Control in Subjects with Poorly Controlled Type 2 Diabetes: Comparison of Two Treatment Algorithms Using Insulin Glargine. Diabetes Care, 28, 1282-1288. http://dx.doi.org/10.2337/diacare.28.6.1282
- Yki-Jarvinen, H., et al. (2007) Initiate Insulin by Aggressive Titration and Education (INITIATE): A Randomized Study to Compare Initiation of Insulin Combination Therapy in Type 2 Diabetic Patients Individually and in Groups. Diabetes Care, 30, 1364-1369. http://dx.doi.org/10.2337/dc06-1357
- Hosaka, T., et al. (2014) Current Issue and Future Strategy of BOT (Basal-supported Oral Therapy). Journal of New Remedies & Clinics, 63, 837-843.
- Meier, J.J., et al. (2013) Hyperglycaemia Is Associated with Impaired Pulsatile Insulin Secretion: Effect of Basal Insulin Therapy. Diabetes, Obesity and Metabolism, 15, 258-263. http://dx.doi.org/10.1111/dom.12022
- Otani, T., et al. (2011) The Safety and Usefulness of BOT (Basal Supported Oral Therapy) Using Insulin (ALOHA Study)—Based on the Result of the Lantus® Drug Use Survey “Investigation of the Concomitant Use of Oral Hypoglycemic Drugs (Type 2 Diabetes). Journal of New Remedies and Clinics, 60, 458-475.
- Odawara, M., et al. (2012) Dosing of Insulin Glargine to Achieve the Treatment Target in Japanese Type 2 Diabetes on a Basal Supported Oral Therapy Regimen in Real Life: ALOHA Study Subanalysis. Diabetes Technology & Therapeutics, 14, 635-643. http://dx.doi.org/10.1089/dia.2011.0220